FIELD: biotechnology.
SUBSTANCE: the invention relates to the use of a composition containing deoxyadenosine, deoxyguanosine, deoxycytidine, deoxythymidine and one or more pharmacologically acceptable nucleoside degradation inhibitors for the treatment of mitochondrial DNA depletion and/or deletion syndrome caused by a defect in the gamma-1 DNA polymerase subunit (POLG-1).
EFFECT: the invention provides restoration of mitochondrial DNA levels, regardless of the severity of the patient's disease, and therefore it is of significant therapeutic value.
8 cl, 1 ex, 3 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DEOXYNUCLEOSIDE THERAPY OF DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS, INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES | 2016 |
|
RU2721492C2 |
| METHOD FOR DETERMINATION OF MTDNA SHARE WITH DELETIONS IN BIOLOGICAL SAMPLES | 2018 |
|
RU2676897C1 |
| METHOD FOR CORRECTION OF MITOCHONDRIAL DYSFUNCTION BY GENETIC CONSTRUCT | 2016 |
|
RU2642972C1 |
| METHOD OF HOMINAL MITOCHONDRIAL GENOME COPYING IN YARROWIA LIPOLYTICA YEAST CELLS | 2016 |
|
RU2660715C2 |
| METHOD FOR MEASURING NUMBER OF COPIES OF HUMAN MITOCHONDRIAL DNA BY DIGITAL POLYMERASE CHAIN REACTION | 2021 |
|
RU2755663C1 |
| NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE | 2023 |
|
RU2809065C1 |
| MITOCHONDRIAL LOCALIZATION PEPTIDE, NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE CONTAINING ITS EXPRESSION VECTOR AND ITS USE | 2023 |
|
RU2817420C1 |
| METHOD FOR DIAGNOSIS OF DISEASE ACCOMPANIED BY INCREASED CELL DEATH, AND SET FOR ITS IMPLEMENTATION | 2016 |
|
RU2630648C2 |
| METHOD FOR ASSESSING GENETIC RISK OF ATHEROSCLEROSIS BASED ON DETERMINATION OF MITOCHONDRIAL GENOME VERSIONS | 2015 |
|
RU2592233C1 |
| METHOD OF PRODUCING FULL-LENGTH HUMAN MITOCHONDRIAL DNA SEQUENCE USING SET OF OLIGONUCLEOTIDES BY MULTIPLEX AMPLIFICATION FOR WORKING WITH DEGRADED DNA SAMPLES | 2021 |
|
RU2818323C2 |
